Suppr超能文献

KCl 诱导的发作性头痛模型中血脑屏障完整性的丧失增强了中枢神经系统药物的递送。

Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery.

机构信息

Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724.

出版信息

eNeuro. 2018 Jul 16;5(4). doi: 10.1523/ENEURO.0116-18.2018. eCollection 2018 Jul-Aug.

Abstract

Cortical spreading depression (CSD) in the CNS is suggested as a common mechanism contributing to headache. Despite strong evidence for CNS involvement in headache disorders, drug development for headache disorders remains focused on peripheral targets. Difficulty in delivering drugs across the blood-brain barrier (BBB) may partially account for this disparity. It is known, however, that BBB permeability is increased during several CNS pathologies. In this study, we investigated BBB changes in response to KCl-induced CSD events and subsequent allodynia in rats. Cortical KCl injection in awake, freely moving rats produced facial allodynia with peak intensity between 1.5 and 3 h and CSD induction within 0.5-2 h postinjection. Brain perfusion of C-sucrose as a marker of BBB paracellular permeability revealed increased leak in the cortex, but not brainstem, beginning 0.5 h post-KCl injection and resolving within 6 h; no changes in tight junction (TJ) proteins occludin or claudin-5 expression were observed. Acute pretreatment with topiramate to inhibit CSD did not prevent the increased BBB paracellular permeability. CNS delivery of the abortive anti-migraine agent sumatriptan was increased in the cortex 1.5 h post-KCl injection. Surprisingly, sumatriptan uptake was also increased in the brainstem following CSD induction, suggesting regulation of active transport mechanisms at the BBB. Together, these results demonstrate the ability of CSD events to produce transient, time-dependent changes in BBB permeability when allodynia is present and to mediate access of clinically relevant therapeutics (i.e., sumatriptan) to the CNS.

摘要

中枢神经系统(CNS)中的皮质扩散性抑制(CSD)被认为是导致头痛的共同机制。尽管有强有力的证据表明 CNS 参与了头痛疾病,但头痛疾病的药物开发仍然集中在外周靶点。药物难以穿过血脑屏障(BBB)可能部分解释了这种差异。然而,已知 BBB 通透性在几种 CNS 病理中增加。在这项研究中,我们研究了 BBB 在 KCl 诱导的 CSD 事件和随后大鼠的痛觉过敏反应中的变化。在清醒、自由活动的大鼠中,皮质内 KCl 注射会导致面部痛觉过敏,峰值强度在 1.5 至 3 小时之间,CSD 诱导在注射后 0.5 至 2 小时之间。作为 BBB 细胞旁通透性标志物的 C-蔗糖脑灌注显示,皮质中漏出增加,但脑桥中没有增加,从 KCl 注射后 0.5 小时开始,并在 6 小时内解决;未观察到紧密连接(TJ)蛋白紧密连接蛋白或 Claudin-5 表达的变化。急性预先用托吡酯抑制 CSD 并不能防止 BBB 细胞旁通透性增加。CSD 诱导后,KCl 注射后 1.5 小时, abortive 抗偏头痛药物舒马曲坦在皮质中的中枢传递增加。令人惊讶的是,CSD 诱导后,脑桥中舒马曲坦的摄取也增加了,这表明 BBB 上主动转运机制的调节。总之,这些结果表明,当存在痛觉过敏时,CSD 事件能够产生短暂的、时间依赖性的 BBB 通透性变化,并介导临床相关治疗药物(即舒马曲坦)进入 CNS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d65e/6071204/721c2ef56742/enu0041826710001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验